Sign Out
Eye Colour Changes: TRAVATAN eye drops may gradually change the eye colour by increasing the number of melanosomes (pigment granules) in melanocytes. Before treatment is instituted, patients must be informed of the possibility of a permanent change in eye colour. The change in iris colour occurs slowly and may not be noticeable for months to years.
Periorbital and eye lid changes: Periorbital and/or eyelid skin darkening has been reported in association with the use of TRAVATAN eye drops.
Periorbital and lid changes including deepening of the eyelid sulcus have been observed with prostaglandin analogues.
TRAVATAN eye drops may gradually change eyelashes in the treated eye(s); these changes were observed in about half of the patients in clinical trials and include: increased length, thickness, pigmentation, and/or number of lashes.
Aphakic Patients: Macular oedema has been reported during treatment with prostaglandin F2a analogues. Use TRAVATAN eye drops with caution in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema.
Iritis/Uveitis: TRAVATAN eye drops should be used with caution in patients with active intraocular inflammation, as well as patients with predisposing risk factors for uveitis.
Effects on ability to drive and use machines: Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines. If blurred vision occurs at instillation, the patient must wait until the vision clears before driving or using machinery.
